Thermo Fisher Scientific (TMO) Other Accumulated Expenses (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Other Accumulated Expenses for 18 consecutive years, with $3.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses rose 19.47% year-over-year to $3.8 billion; the trailing twelve-month figure through Jun 2026 stood at $3.8 billion (up 19.47% YoY), and the FY2025 full-year result was $3.3 billion, up 4.06% from the prior year.
• Other Accumulated Expenses climbed to $3.8 billion in Q2 2026 per TMO's latest filing, from $3.7 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.8 billion in Q2 2026 and bottomed at $2.8 billion in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $3.2 billion across 5 years, with a median of $3.2 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses surged 58.89% in 2022, then declined 11.17% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $3.4 billion in 2022, then decreased by 3.22% to $3.2 billion in 2023, then slipped by 1.45% to $3.2 billion in 2024, then gained by 4.06% to $3.3 billion in 2025, then grew by 14.84% to $3.8 billion in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $3.8 billion, $3.7 billion, and $3.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.